At a glance
ClinicalIndex Comparison Record- ✓Consecutive patients with evidence of small bowel motility disorders referred to or established patients at the Gastroenterology and Motility Center at Northwell Health System
- ✓Age 18 to 70 years
- ✓Small bowel motility disorder confirmed by wireless motility capsule (WMC) testing showing delayed transit >6 hours
- ✓Capable of understanding the study and providing informed consent
- ✕Age <18 or >70 years
- ✕Pregnancy (confirmed by urine pregnancy test)
- ✕History of gastric bezoar
- ✕Disorders of swallowing or severe dysphagia to food or pills
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants
In Brief
A Phase 2 clinical trial evaluating Lanreotide for Gastrointestinal Motility Disorder and Intestinal Disease. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
This is a human research study looking at the effectiveness of Lanreotide (study medication) in treating small bowel motility disorders. It is similar to a natural hormone somatostatin that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a growth hormone-inhibiting hormone. Lanreotide is a man made hormone and is a long acting medication that is given once a month. It is marketed with a trade name "Somatuline Depot". It is given deep subcutaneously (deep within the layers of the skin) in the superior external quadrant of the buttock. Injection site will be alternated on subsequent injections.
Study Details
Timeline
Interventions
Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart